TNFRSF11B and neoplasm: In addition, when expressed in immune cells, NK, and PBLs, respectively, TR1-scFv-CAR induced CAR-mediated cytolytic activity, demonstrating that CARs targeting DRs could be used as anticancer therapeutic tools to induce tumor regression [218].